U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.

Approval Year

1950
102
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ACTHAR

Approved Use

H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.

Launch Date

-6.1534077E11
Primary
Approved
8429
ACTHAR

Approved Use

H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.

Launch Date

-6.1534077E11
PubMed

PubMed

TitleDatePubMed
Reversible cerebral atrophy and corticotrophin.
1979 Jul 28
Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases.
1980 Feb
Aicardi's syndrome: are corticosteroids teratogens?
1981 Jan
[Collateral transient behavioural changes during ACTH therapy in infantile generalized epilepsy (author's transl)].
1981 Mar-Jun
Sequential CT studies of 24 children with infantile spasms on ACTH therapy.
1983 Aug
'Dystonia'-like postural asymmetry after microinjection of ACTH N-terminal fragments but not after ACTH1-39 in rat brainstem suggests role of neuropeptide mutation in genetic movement disorder.
1984 Feb 27
Acute-onset transient hydrocephalus after suspension of ACTH therapy for infantile spasms: a case report.
1984 Jun
ACTH and vasopressin responses to insulin-induced hypoglycemia in intact and neurohypophysectomized conscious dogs.
1991 Jan
Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone.
1995 Nov-Dec
Nelson's syndrome due to an intracavernous corticotropin-secreting adenoma.
1999 May-Jun
Effects of chronic 'Binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32.
1999 Sep
Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis.
2003 Apr
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.
2005 Dec 6
Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause.
2006 Apr
Aryl hydrocarbon receptor activation impairs cortisol response to stress in rainbow trout by disrupting the rate-limiting steps in steroidogenesis.
2006 Apr
Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.
2009

Sample Use Guides

In Vivo Use Guide
The usual dose of Corticotropin is 40-80 units given intramuscularly or subcutaneously every 24-72 hours.
Route of Administration: Other
Substance Class Protein
Created
by admin
on Sat Dec 16 00:29:52 UTC 2023
Edited
by admin
on Sat Dec 16 00:29:52 UTC 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
K0U68Q2TXA
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
Corticotropin
GREEN BOOK   INN   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
CORTROPHIN
Brand Name English
CORTICOTROPIN [ORANGE BOOK]
Common Name English
ADRENOCORTICOTROPHIN
HPUS  
Common Name English
CORTICOTROPIN [USP-RS]
Common Name English
25-ASP-30-GLN-CORTICOTROPIN PORCINE
Common Name English
ACTH [MI]
Common Name English
CORTICOTROPIN [VANDF]
Common Name English
CORTICOTROPIN (ACTH)
Common Name English
ACTHAR
Brand Name English
ACTH
MI  
Brand Name English
CORTICOTROPHIN
Common Name English
CORTICOTROPIN [USP IMPURITY]
Common Name English
ADRENOCORTICOTROPIC HORMONE
Common Name English
corticotropin [INN]
Common Name English
Corticotropin [WHO-DD]
Common Name English
CORTICOTROPIN [GREEN BOOK]
Common Name English
ADRENOCORTICOTROPHIN [HPUS]
Common Name English
PURIFIED CORTROPHIN GEL
Brand Name English
.ALPHA.1-39-CORTICOTROPIN (SWINE), 25-L-ASPARTIC ACID-30-L-GLUTAMINE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.1025
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 14674-6
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
WHO-VATC QH01AA01
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 15042-5
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 2141-0
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
FDA ORPHAN DRUG 168103
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
FDA ORPHAN DRUG 399113
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 6879-1
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 2140-2
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 16652-0
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 66732-9
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000175941
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
WHO-ATC H01AA01
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
Code System Code Type Description
EVMPD
SUB01465MIG
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
CAS
12427-33-7
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
DRUG BANK
DB01285
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
FDA UNII
K0U68Q2TXA
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
CHEBI
3892
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
RXCUI
376
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1201610
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
LACTMED
Corticotropin
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
INN
1366
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
DRUG CENTRAL
4931
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
RS_ITEM_NUM
1149004
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
IUPHAR
3633
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
MERCK INDEX
m1395
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY Merck Index
DAILYMED
K0U68Q2TXA
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
NCI_THESAURUS
C212
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
PUBCHEM
16132265
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
MESH
D000324
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
Related Record Type Details
REPOSITORY CORTICOTROPIN
SUB_CONCEPT->SUBSTANCE
MELANOCORTIN RECEPTOR 1
TARGET -> AGONIST
Binding Assay
IC50
Corticotropin zinc hydroxide
INGREDIENT -> STARTING MATERIAL
ADRENOCORTICOTROPIC HORMONE RECEPTOR
TARGET -> AGONIST
Related Record Type Details
Corticotropin
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966